Is Inspire Medical Systems (INSP) Undervalued After Its Earnings Beat And Higher 2026 Guidance?
Why Inspire Medical Systems Stock Is Back On Investors’ Radar
Inspire Medical Systems (INSP) moved into focus after reporting second quarter 2026 adjusted earnings per share of $0.14, ahead of analyst expectations, and lifting its 2026 revenue and earnings outlook.
The updated guidance signals management confidence despite ongoing U.S. coding and reimbursement challenges, which were linked to a decline in domestic sales. International revenues provided some support to the revised view.
Inspire Medical Systems’ share price has been volatile, with a 50.86% 90 day share price return from a low base, even as the year to date share price return is down 32.65% and the 1 year total shareholder return has declined 28.01%.
The earnings beat and higher 2026 guidance appear to have improved sentiment in the short term. However, the 3 year and 5 year total shareholder returns, both down more than 70%, show how much long term holders have already absorbed in terms of risk and repricing.
Compare the rebound in Inspire Medical Systems with a curated group of healthcare stocks that pair earnings momentum with balance sheet strength in our list of solid balance sheet and fundamentals (53 results).
Inspire Medical Systems just reminded investors it has a real business story, not just a falling share price. After such a sharp rebound from a depressed level, the question now is whether the stock actually offers value.
Most Popular Narrative: 3% Overvalued
The most followed narrative pegs Inspire Medical Systems’ fair value at $60.40, slightly below the last close of $62.14. This frames the recent rebound in a tighter valuation range.
The analysts have a consensus price target of $60.4 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $85.0, and the most bearish reporting a price target of just $40.0.
Want to understand why earnings are projected to move one way while revenues are modeled another? Curious how margin assumptions and the chosen future P/E work together? The full narrative lays out the exact path those inputs take to arrive at that $60.40 fair value.
Result: Fair Value of $60.40 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points for Inspire Medical Systems, including lingering coding and reimbursement uncertainty, as well as the risk that higher marketing spend keeps margins under strain.
Find out about the key risks to this Inspire Medical Systems narrative.
Another View on Inspire Medical Systems’ Valuation
The analyst narrative calls Inspire Medical Systems about 3% overvalued at $60.40, yet the current price around $62 sits roughly 28% below the estimate of future cash flow value of $86.77 from our DCF model. These two frameworks point in different directions, so which one do you find more convincing?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With mixed signals on valuation and sentiment around Inspire Medical Systems, now is a good time to review the data for yourself and decide how the risk reward trade-off looks in your portfolio. To help you get started, you can quickly scan the 3 key rewards and 1 important warning sign.
Looking For More Investment Ideas Beyond Inspire Medical Systems?
If Inspire Medical Systems has you rethinking your portfolio, now is the moment to widen your search with a few targeted stock ideas you can act on quickly.
- Spot potential bargains with resilient fundamentals by scanning our 52 high quality undervalued stocks that match strong quality signals with appealing pricing.
- Strengthen your income stream by reviewing the 11 dividend fortresses that may help you build more predictable cash flows.
- Reduce portfolio stress by focusing on stability first through a 79 resilient stocks with low risk scores that screens for companies with steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com